Evidence map›Paper›PMID 29449276›Full record

Trial reportBlood2018

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.

Frank Vari, David Arpon, Colm Keane, Mark S Hertzberg, Dipti Talaulikar, Sanjiv Jain, Qingyan Cui, Erica Han, Josh Tobin, Robert Bird and 5 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 1 pooled it
25.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 1 synthesis or guideline pooled it, 304 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. PD-1Journal of experimental & clinical cancer research : CR · 2025
    Article

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Frank VariUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
David ArponUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Colm KeaneUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Mark S HertzbergHaematology, Prince of Wales Hospital, Sydney, NSW, Australia.
Dipti TalaulikarCanberra Hospital, Canberra, ACT, Australia.
Sanjiv JainCanberra Hospital, Canberra, ACT, Australia.
Qingyan CuiUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Erica HanUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Josh TobinUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Robert BirdDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Donna CrossDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Annette HernandezDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Clare GouldUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Simone BirchDepartment of Pathology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Maher K GandhiUniversity of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1000-5393
Translational Research Institute · AUPrincess Alexandra Hospital · AUAustralian National University · AUCanberra Hospital · AUPrince of Wales Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Much focus has been on the interaction of programmed cell death ligand 1 (PD-L1) on malignant B cells with programmed cell death 1 (PD-1) on effector T cells in inhibiting antilymphoma immunity. We sought to establish the contribution of natural killer (NK) cells and inhibitory CD163

Indexed as

Models, ImmunologicalTumor EscapeAdultAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBleomycinCyclophosphamideDacarbazineDoxorubicinFemaleHodgkin DiseaseHumansKiller Cells, NaturalLymph NodesLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, Murine-DerivedB7-H1 AntigenBleomycinCD274 protein, humanCyclophosphamideDacarbazineDoxorubicinNeoplasm ProteinsPDCD1 protein, humanPrednisoneProgrammed Cell Death 1 ReceptorR-CHOP protocolRituximabVinblastineVincristine

Identifiers

PMID29449276
PMCPMC5922274
OpenAlexW2785652708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.